Galectin Therapeutics (GALT) to Announce Earnings on Thursday

Galectin Therapeutics (NASDAQ:GALT) is expected to announce its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect the company to post earnings of ($0.09) per share for the quarter. Interested persons may review the information on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Friday, August 21, 2026 at 9:30 AM ET.

Galectin Therapeutics (NASDAQ:GALT) last posted its earnings results on Friday, May 15th. The company reported ($0.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.02). On average, analysts expect Galectin Therapeutics to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Galectin Therapeutics Price Performance

Shares of GALT stock opened at $3.13 on Wednesday. Galectin Therapeutics has a 1-year low of $2.03 and a 1-year high of $7.13. The firm has a market cap of $206.14 million, a PE ratio of -7.63 and a beta of 0.41. The company has a 50-day moving average of $3.55 and a two-hundred day moving average of $2.99.

Wall Street Analysts Forecast Growth

GALT has been the subject of a number of research analyst reports. Wall Street Zen raised shares of Galectin Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, June 13th. Zacks Research lowered shares of Galectin Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Monday, July 13th. HC Wainwright restated a “buy” rating and issued a $11.00 price objective on shares of Galectin Therapeutics in a report on Tuesday, June 23rd. Finally, Weiss Ratings upgraded Galectin Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, June 18th. One research analyst has rated the stock with a Buy rating and two have given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Reduce” and an average target price of $11.00.

Insider Transactions at Galectin Therapeutics

In other news, insider Khurram Jamil sold 47,467 shares of the company’s stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $5.04, for a total transaction of $239,233.68. Following the completion of the transaction, the insider directly owned 2,037 shares of the company’s stock, valued at approximately $10,266.48. This represents a 95.89% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Harold H. Shlevin sold 22,268 shares of the stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $5.04, for a total value of $112,230.72. Following the completion of the transaction, the director owned 6,500 shares in the company, valued at approximately $32,760. The trade was a 77.41% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 90,162 shares of company stock valued at $438,464 over the last ninety days. 52.60% of the stock is owned by company insiders.

Institutional Trading of Galectin Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in GALT. Virtu Financial LLC grew its stake in Galectin Therapeutics by 37.4% during the 4th quarter. Virtu Financial LLC now owns 53,551 shares of the company’s stock worth $223,000 after buying an additional 14,583 shares during the last quarter. Invesco Ltd. purchased a new stake in Galectin Therapeutics in the fourth quarter valued at approximately $43,000. XTX Topco Ltd purchased a new stake in Galectin Therapeutics in the fourth quarter valued at approximately $216,000. Wellington Management Group LLP acquired a new stake in shares of Galectin Therapeutics in the fourth quarter valued at approximately $592,000. Finally, Millennium Management LLC boosted its holdings in shares of Galectin Therapeutics by 113.3% in the fourth quarter. Millennium Management LLC now owns 235,508 shares of the company’s stock valued at $980,000 after acquiring an additional 125,086 shares during the period. Institutional investors and hedge funds own 11.68% of the company’s stock.

About Galectin Therapeutics

Galectin Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel therapies that target galectin proteins, which are implicated in fibrotic, inflammatory and malignant diseases. The company’s lead product candidate, belapectin (formerly GR-MD-02), is a galectin-3 inhibitor being evaluated in Phase 2 clinical trials for nonalcoholic steatohepatitis (NASH) with cirrhosis. In addition to its core pipeline in fibrotic liver disease, Galectin Therapeutics continues to explore the potential of its galectin inhibitors in oncology and other indications driven by abnormal tissue remodeling.

Founded in 2000, the company is headquartered in Norcross, Georgia, where it oversees discovery research, preclinical studies and clinical trial coordination.